AR ARG - 1hH6 E . 1. 0U Pon Dz NaMo&CuoitReasnt 7.

AR ARG -- IKE FLUOROCSHTEAMTUISCALRSEVIIENWBLOOD : =s/22719, BG e ooJnrognaMgnaciyhca3i0f,niup1o9er7ro8fc,laurob3roMonsinsifunorrfbmal:codeo-dDauctoifPvoeentmmpalotfoeyrefieiasnldsie.nxgpsosoefdantoic : lfaloiutaohdroilrdneeevmebillssowtosdeolrervdeuelsst.sof--ag1ensteowrsia7tt1oehpdop-cpmwewreiearrteaie-oifntnos-u-rnewadhn.eodgrfee"Hioher 4f8lu-o8r1ipnpem,in h3uMmarnesporitssaptphaatrenstomley tnorramcael,levie.el. oflesosrgatnhiacn 1 ppm.

71-00/-13 78s frit DuPont Haskell Laboratory AR 224-1000 FeI --00-00 32D muy 0m Gaol 000000 > He224-155 `UDrS.

BACK TO MAIN CEntrE Analytical Laboratories, Inc. 3048 Research Drive State Ca?

. oySKT uttP.eRest, PD.

" Wildlife International, Ltd. -1- NON-GLP STUDY: DETERMINATION OF THE SOLUBILITY OF PFOS IN WILDLIFE INTERNATIONAL, LTD.

Fraunhofer ITEM Final Report 01 G 00 0 02 [Appendix H // EXYGEN Data] 28 Day Repeated Dermal Contact Study of 3M Test Articles in Sprague-Dawley Rats Page 1 of 13 Appendix H: PFOS, PFHS and M570 Residues in Rat Blood Serum (EXYGEN Data) Fraunhofer ITEM Final Report 01 G 00 0 02 [Appendix H // EXYGEN Data] 28 Day Repeated Dermal Contact Study of 3M Test Articles in Sprague-Dawley Rats Page 2 of 13 Sex // Gr.

sam Ar226-/510 Date: 2-24-04 IM tetra Loss Report Nos FACT Tot 1 3M Medical Department Study Number: T-7211.1 3M Strategic Toxicology Laboratory Protocol Study No.

URGENT : PPL PFAS - risque pour le groupe SEB CARANTINO Benjamin [EE ACCUSTHTODSOoRmOeFFI sic IN ocI 75: 1 I 0 o 1 v . . ico E >>|E EN 00 :CE HOUViic: 0. cone -- Bonjour tous JignraelboncdeismastuinceptatreSbEoBucle pour signalr un point particuirement problmatiaue & article 1 de la PPL Thiery, qui fa t Latrjudsacqtuiiocn anctteureplrletdejulsaqPuP'iLcinptaerrdlireaiatdmaiuni1s"trjaatnivoinesr 2c0o2m5mteouisslaesnplreosdsuietusseenmcboanltaagctesavaelcimIeanltiamiernet,atnioontahmummaeinnte.fmCesla avait ppuaisstaiueesl.e rDegsleomres,ntFePnPjeWuRnpdrustvroltelleduer iinntteerrddiiccttioinoneutraoiptaebnlnee, aula-dmelmdeudcataer.actre Inconventionnel au regard du cacre REACH, lSeEs8flmeenibsliegsnaPlFeASqureslesutralnetcst3uraetdeemcptraatrtuirceleqeusitqquuipnetnetrlieruaristmagcahlienmeesn3t ceasfrevetements de podles PFAS (du PTFE, ton.) et Sperloodnucetuiosnudneecteeslldeeiunxtegrdaimcmteiosn,toucherait 40% de leur CA et impliquerait I fermeture de fensemble de leurs ites frangais de tant donn les impacts pour une industri ts reprsente dans nos teritoires (14 sites de SEB seul en France) et intensive en peas. sien vous, Benjamin E-- E 1 I 1] EE -- a ------ E-- E I ------ a -- ] -- u

AONT T FICHA DEPEADKASPDAION,SS.

2ca%l o=s| E E| g3 8= go &| 3 > al 78 a @ & 5 = 8g 2.

AR226-2049 Voluntary "UEIP, Ammonium Perflaorooctanoate Voluntary Use and Exposure Information Profile Ammonium Perfluorooctanoate (APFO) X.

AR226-2091 WASHIHSTOH WORKS C-8 INDUSTRIAL HYGIENE EN6INEER2NS CONTROLS NORK RHLES, PROTECTIVE CLOTHING, RESPIRATORY PROTECTION, ETC.

Substances PTFE CAS No.

Position statement by MedicalMountains GmbH on the proposal for a restriction on per- and polyfluoroalkyl substances (PFASs) Version 2.0 www.medicalmountains.de POSITION STATEMENT (MedicalMountains MED ALLIANCE BW File Version 2.0 August 2023 Contact: MedicalMountains GmbH Katharinenstrasse 2 D-78532 Tuttlingen Germany Julia Steckeler CEO @medicalmountains.de Phone +49 7461 969721-2 Meinrad Kempf Project manager M@medicalmountains.de Phone +49 7461 969721-8 www.medicalmountains.de 1 Contents 1.